Readystate Asset Management LP Acquires New Position in Replimune Group, Inc. $REPL

Readystate Asset Management LP acquired a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 138,488 shares of the company’s stock, valued at approximately $1,059,000. Readystate Asset Management LP owned approximately 0.17% of Replimune Group as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in REPL. International Assets Investment Management LLC acquired a new position in Replimune Group in the fourth quarter worth $29,000. Russell Investments Group Ltd. lifted its position in shares of Replimune Group by 3,638.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the last quarter. CWM LLC lifted its position in shares of Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after buying an additional 6,873 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Replimune Group in the 2nd quarter valued at about $69,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analysts Set New Price Targets

REPL has been the topic of several analyst reports. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. Jefferies Financial Group reiterated a “hold” rating and set a $2.00 price target (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target for the company in a report on Tuesday, June 30th. HC Wainwright reaffirmed a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. Finally, Piper Sandler downgraded shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Friday, April 10th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Replimune Group presently has an average rating of “Hold” and a consensus target price of $8.86.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by company insiders.

Trending Headlines about Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Trading activity has been unusually heavy, suggesting investors are repositioning ahead of the FDA’s upcoming advisory committee meeting. The current move appears more consistent with volatility and a potential rebound after the prior selloff than with a new fundamental catalyst.
• Negative Sentiment: FDA staff reviewers questioned whether Replimune’s RP1 therapy has demonstrated sufficient efficacy in advanced melanoma. The concerns have raised expectations that the agency could reject or delay approval, making the advisory committee meeting a major near-term risk for REPL. Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy
• Negative Sentiment: Multiple law firms—including Kirby McInerney, Glancy Prongay Wolke & Rotter, and Howard G. Smith—announced investigations into whether Replimune or its executives violated securities laws or made misleading disclosures. These announcements do not establish wrongdoing, but they add legal and reputational overhang and could potentially lead to shareholder claims. Kirby McInerney investigation announcement
• Negative Sentiment: The investigations follow the FDA briefing-document disclosure that prompted a major one-day decline in REPL shares, as investors reassessed the probability of RP1 approval and the value of Replimune’s pipeline. Replimune shares fall on negative FDA comments

Replimune Group Price Performance

NASDAQ REPL opened at $5.41 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. The firm has a market capitalization of $454.12 million, a price-to-earnings ratio of -1.60 and a beta of 0.86. The company has a 50 day simple moving average of $9.35 and a 200-day simple moving average of $7.37. Replimune Group, Inc. has a 52-week low of $1.50 and a 52-week high of $12.50.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Equities research analysts predict that Replimune Group, Inc. will post -2.44 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.